1. Home
  2. ZDAI vs AKTX Comparison

ZDAI vs AKTX Comparison

Compare ZDAI & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZDAI

Primega Group Holdings Limited Ordinary Shares

N/A

Current Price

$1.64

Market Cap

13.6M

ML Signal

N/A

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

N/A

Current Price

$9.03

Market Cap

15.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZDAI
AKTX
Founded
2022
N/A
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
General Bldg Contractors - Nonresidential Bldgs
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.6M
15.4M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
ZDAI
AKTX
Price
$1.64
$9.03
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$33.50
AVG Volume (30 Days)
47.3K
41.9K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.12
52 Week High
$11.48
$29.32

Technical Indicators

Market Signals
Indicator
ZDAI
AKTX
Relative Strength Index (RSI) 43.62 55.37
Support Level $1.62 $0.21
Resistance Level $2.04 $15.50
Average True Range (ATR) 0.17 0.78
MACD 0.01 0.26
Stochastic Oscillator 13.00 75.07

Price Performance

Historical Comparison
ZDAI
AKTX

About ZDAI Primega Group Holdings Limited Ordinary Shares

DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: